Want to see INBP full AI Analyst Report?
INBP Stock Chart & Stats
$0.16
<$0.01(6.38%)
At close: 4:00 PM EDT
$0.16
<$0.01(6.38%)
Day’s Range― - ―
52-Week Range$0.14 - $0.42
Previous CloseN/A
Volume7.89K
Average Volume (3M)15.15K
Market Cap
$4.97M
Enterprise Value$3.42M
Total Cash (Recent Filing)$5.83M
Total Debt (Recent Filing)$3.35M
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding31,059,610
10 Day Avg. Volume31,065
30 Day Avg. Volume15,153
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.53
Price to Sales (P/S)0.20
P/FCF Ratio5.77
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue0.07
Enterprise Value/Gross Profit1.53
Enterprise Value/Ebitda61.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Free Cash FlowSustained positive operating and free cash flow despite a net loss indicates the business is generating internal liquidity. This durable cash cushion can fund working capital, modest capex and equipment purchases, reduce short-term financing needs, and provide flexibility while margins recover.
Low Leverage / Conservative Balance SheetRelatively low debt levels give the company resilience against revenue volatility and reduce interest burden risk. This structural financial flexibility supports refinancing options, preserves borrowing capacity for operational needs, and lowers insolvency risk over the medium term.
CDMO Model In NutraceuticalsA contract-manufacturing model for supplements offers recurring B2B revenue, long lead-time customer contracts and service stickiness through formulation and packaging expertise. These structural capabilities create entry barriers and revenue visibility when customer demand is stable.
Bears Say
Revenue Decline And Negative MarginsA marked TTM revenue decline and negative operating results signal weakening demand or lost customer volume. Persistent top-line deterioration undermines margin recovery, reduces reinvestment capacity, and increases reliance on financing or pricing actions to restore profitability over the medium term.
Shrinking Gross MarginsA secular decline in gross margin suggests structural pressure from cost inputs, pricing squeeze, or unfavorable product mix. Lower gross margins limit the firm's ability to absorb SG&A and R&D, constraining sustainable EBITDA generation and long-term competitiveness in the CDMO market.
Reliance On Amended Credit FacilitiesDependence on extending and reshaping credit lines highlights ongoing liquidity management needs. Smaller replacement equipment financing and convertible structures can increase refinancing risk or eventual dilution, leaving the company exposed if margins and cash flows do not stabilize.
Integrated BioPharma News
INBP FAQ
What was Integrated BioPharma Inc’s price range in the past 12 months?
Integrated BioPharma Inc lowest stock price was $0.14 and its highest was $0.42 in the past 12 months.
What is Integrated BioPharma Inc’s market cap?
Integrated BioPharma Inc’s market cap is $4.97M.
When is Integrated BioPharma Inc’s upcoming earnings report date?
Integrated BioPharma Inc’s upcoming earnings report date is Sep 30, 2026 which is in 41 days.
How were Integrated BioPharma Inc’s earnings last quarter?
Integrated BioPharma Inc released its earnings results on May 08, 2026. The company reported -$0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.027.
Is Integrated BioPharma Inc overvalued?
According to Wall Street analysts Integrated BioPharma Inc’s price is currently Overvalued.
Does Integrated BioPharma Inc pay dividends?
Integrated BioPharma Inc does not currently pay dividends.
What is Integrated BioPharma Inc’s EPS estimate?
Integrated BioPharma Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrated BioPharma Inc have?
Integrated BioPharma Inc has 31,059,610 shares outstanding.
What happened to Integrated BioPharma Inc’s price movement after its last earnings report?
Integrated BioPharma Inc reported an EPS of -$0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Integrated BioPharma Inc?
Currently, no hedge funds are holding shares in INBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Integrated BioPharma Inc
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment provides warehousing and fulfilment services; and distributes raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Technical Analysis
Natural Alternatives International
―
Sow Good
―
FitLife Brands
―
Bon Natural Life
―
Healthy Choice Wellness Corp. Class A
―